Developing tests to identify cancer in patients with vague symptoms
Official title: Rapid Diagnostic Centre Biomarker Study
Run by Royal Marsden NHS Foundation Trust · NCT05876676 · Data updated 2026-11-12
This study is testing new blood and non-blood tests to see if they can quickly identify cancer in people with unclear but worrying symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Royal Marsden NHS Foundation Trust Academic / other |
| Locations | 10 sites (Abergavenny and 9 other locations) |
| Status | Recruiting |
| Started | July 10, 2023 |
| Main results expected | July 10, 2027 |
| Study ends | July 10, 2032 |
| Registry record updated | April 17, 2025 |
| Trial ID | NCT05876676 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years referred to an RDC for suspected cancer investigation.
✕Probably not a fit
Patients with a current confirmed diagnosis of active malignancy or those who have been treated for cancer within the last five years may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on Rapid Diagnostic Centres (RDCs) in England, which are designed to diagnose patients presenting with non-specific but concerning symptoms of cancer. The study aims to develop a new blood or non-blood test that can quickly identify patients who have cancer or are at higher risk of developing it. By improving the diagnostic process, the study seeks to enhance patient outcomes and streamline cancer screening programs. The research will analyze how vague symptoms relate to underlying health conditions and the effectiveness of RDCs.
Why it matters
Potential benefit: If successful, this study could lead to earlier cancer detection and better monitoring for at-risk patients.
How similar studies have gone: While the concept of RDCs is established, the specific approach of developing new diagnostic tests for vague symptoms is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients referred to undergo investigation for suspected cancer within a non-tumour site specific RDC * Age \> 18 years Exclusion Criteria: * Previously treated (treatment completed within 5 years preceding recruitment) * Current confirmed diagnosis of active malignancy * Unable to or unwilling to give informed consent
Where it's running
-
Aneurin Bevan University Local Health Board
Abergavenny, United Kingdom Recruiting -
Glan Clwyd
Bodelwyddan, United Kingdom Recruiting -
Harrogate and District NHS Foundation Trust
Harrogate, United Kingdom Recruiting -
Kingston and Richmond NHS Foundation Trust
Kingston, United Kingdom Recruiting -
Ysbyty Gwynedd
Llandudno, United Kingdom Recruiting -
Chelsea and Westminster Hospital NHS Foundation Trust - Chelsea and Westminster
London, United Kingdom Recruiting
Show 4 more locations
-
Chelsea and Westminster Hospital NHS Foundation Trust - West Middlesex
London, United Kingdom Recruiting -
North Middlesex University Hospital NHS Trust
London, United Kingdom Recruiting -
South Tees Hospitals NHS Foundation Trust
Middlesbrough, United Kingdom Recruiting -
Northern Care Alliance NHS Foundation Trust
Salford, United Kingdom Recruiting
Study contacts
- Principal investigator: Richard Lee, Dr — Royal Marsden NHS Foundation Trust
- Study coordinator: Serwaa Lashley
- Email: rdcbio@rmh.nhs.uk
- Phone: 020 7808 2603
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Genetic Risk Profiling in Prostate Cancer: Patient and Provider Perspectives
This study asks patients and their doctors how genetic risk profiling for prostate cancer might fit into routine care and decision-making.
-
Short-course CT online-adaptive radiotherapy for post-operative endometrial cancer
This trial tests whether delivering post-operative radiotherapy in 5 sessions using CT online-adaptive radiotherapy is safe and feasible for endometrial cancer patients.
-
ctDNA-guided precision care for lung, GIST, colorectal, biliary, and ovarian cancers
This trial tests a blood test that looks for tumor DNA in patients with several cancers to help guide personalized treatment decisions.
-
Personalised neoadjuvant therapy planning for adults with high‑risk soft tissue sarcoma
This project tests whether analyzing tumor tissue and clinical data can help guide neoadjuvant chemotherapy decisions for adults with high‑risk soft tissue sarcomas.
-
Digital exercise program with live virtual group sessions for men on hormone therapy during radiotherapy
This program will test whether a digital exercise program with live virtual group sessions helps men with prostate cancer who are starting or receiving hormone therapy with radiotherapy stick to exercise recommendations and improve health and fatigue.
-
Immediate breast reconstruction using 3D imaging and simulation to measure effects of radiotherapy
This project will test whether 3D surface photos and simulated images help women having a mastectomy with immediate reconstruction feel more confident about their likely appearance, help surgeons plan to reduce later correction surgery, and measure how radiotherapy changes breast shape.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.